Science & Enterprise subscription

Follow us on Twitter

  • Findings from a Pew Research Center survey released this week show more Americans with smartphones use their phones…
    about 24 hours ago
  • New post on Science and Enterprise: Infographic – Phones Top Internet Access Method #Science #Business
    about 24 hours ago
  • Results from a small-scale clinical trial show an implanted device that stimulates the vagus nerve helps reduce the…
    about 2 days ago
  • New post on Science and Enterprise: Nerve Stimulation Reduces Arthritis Inflammation #Science #Business
    about 2 days ago
  • The Bill and Melinda Gates Foundation is backing research to combine a microscopy technique that grows the size of…
    about 2 days ago

Please share Science & Enterprise

Foundation, Pfizer Collaborate on Alzheimer’s Targets

Illustration of brain (NIDA)

(National Institute of Drug Abuse)

11 February 2015.  Alzheimer’s Drug Discovery Foundation and Pfizer’s Centers for Therapeutic Innovation are joining forces to sponsor research to find new Alzheimer’s disease drug targets. Financial details of the collaboration were not revealed.

The foundation and Pfizer plan to invest in project teams of Pfizer and academic scientists to translate academic research into candidates for small molecule drugs to treat Alzheimer’s disease and related dementias. The initial focus of the collaboration is expected to be new Alzheimer’s drug targets, with the deadline for pre-proposal submissions set for 13 February 2015.

Pfizer’s Centers for Therapeutic Innovation is a research and development network that partners with 25 academic medical centers and foundations to combine entrepreneurial approaches with collaborative science to bridge the gap between basic research and new treatments. The centers are located near academic research campuses in New York, Boston, San Francisco, and San Diego. Other foundation partners include Alliance for Lupus Research and Crohn’s and Colitis Foundation of America, with whom Pfizer shares decision-making on selecting projects for sponsorship and evaluating project progress.

Project teams will receive funding from both Alzheimer’s Drug Discovery Foundation and Pfizer, as well as access to Pfizer’s drug discovery resources, and the foundation’s expertise in Alzheimer’s disease research. Participation is open to current academic medical centers under Pfizer’s Centers for Therapeutic Innovation.

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.